Delivery Order SPE2DB22D2206-SPE2DB25FJZ73
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,981.60 to AmerisourceBergen Drug Corp for GAMUNEX-C, a 40-gram/400 milliliter immunoglobulin vial. The contract, issued on August 6, 2025, carries a firm fixed price and is scheduled for completion by August 27, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Gamunex-C 5 gram/50 milliliter vials with a ceiling value of $1,214.68. This is a firm fixed-price delivery order without set-aside designation, with an ultimate completion date of September 15, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with a firm fixed price. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for GAMUNEX-C 5 gram/50 milliliter vials valued at $2,429.36 with a firm fixed-price contract type. This award represents a non-set-aside, competitively awarded delivery order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical support vehicle valued at approximately $1 billion and running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gamunex-C 5 gram/50 milliliter vials valued at $3,644.04 with a completion date of October 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,937.12 to AmerisourceBergen Drug Corp for GAMUNEX-C 1 gram/10 milliliter vials on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $116,360 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of October 8, 2025, and performance to be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, demonstrating the contractor's ability to compete...
- The Defense Logistics Agency awarded a $40,532.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials, with an ultimate completion date of August 22, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of GAMUNEX-C 40 Gram/400 mL vials valued at $4,654.40 with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJZ73Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of GAMUNEX-C 5 gram/50 milliliter vials valued at $3,036.70. This non-set-aside, firm fixed-price delivery order will be completed by October 9, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle active through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains an extensive portfolio of federal medical contracts with DLA covering a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. The company's competitively awarded contracts reflect its capability to serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for GAMUNEX-C, an immunoglobulin replacement therapy, exemplifies the company's consistent role in supplying specialized pharmaceutical products to support military healthcare requirements globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 9/18/25 |